OA-629 - Favorable outcomes with short, all-oral regimen for rifampicin-resistant tuberculosis (ShORRT) in the DR Congo
Speakers:
- Sissy Musala, National TB Program, Democratic Republic of the Congo
OA-424 - Evaluating lineage-specific response to tuberculosis treatment regimens using clinical Mycobacterium tuberculosis complex isolates
Speakers:
- Fatou Faal, Medical Research Council unit The Gambia at London School of Hygiene and Tropical Medicine, The Gambia
OA-463 - Proportions, patterns and hotspots of group a drug-resistant tuberculosis in the Western Cape: insights from routinely collected laboratory data
Speakers:
- Erick Auma, Stellenbosch University, South Africa
OA-230 - Pharmacokinetic considerations in managing tuberculosis in patients with type-2 diabetes mellitus
Speakers:
- Augustine Boadu Asare, University of Ghana, Ghana
OA-535 - Association of human Cytomegalovirus exposure with tuberculosis disease in TB presumptive South African adults
Speakers:
- Derrick Semugenze, Makerere University and University of Amsterdam, Uganda
OA-724 - Pilot phase 2b N-Acetylcysteine trial: a promising solution for protecting kidney and liver health in drug-resistant tuberculosis treatment
Speakers:
- Stellah Mpagama, Kibong'oto Infectious Diseases Hospital, Tanzania